ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News
NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD
ALNY Latest News, Press Relases and Analysis
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: AXSM
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: GSK
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been […]
Is Zscaler, Inc. (ZS) the Best Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Zscaler, Inc. (NASDAQ:ZS) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been on […]
Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires
We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and […]
I'm in my 30s and just got married. I want to sell my home, move in with my spouse. Is selling the best move?
There are many things to consider when selling a home. Here's how to navigate them.
Is AppLovin Corporation (APP) the Best Long Term Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AppLovin Corporation (NASDAQ:APP) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders with […]
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive […]
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: JAZZ
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam. U.S. District Judge Jennifer Rochon in Manhattan said Adrian Heilbut, Jesse Brodkin, Enea Milioris, David Bredt and Geoffrey Pitt could try to prove that Cassava knew or should have known that it could not win its defamation lawsuit against them, which it dismissed in August.
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio.
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer
Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech and put it in competition with Pfizer Inc.
Mentions: PFE
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
